Role of lupeol and its ester on cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats.
Cyclophosphamide, an alkylating agent widely used in cancer chemotherapy, causes fatal cardiotoxicity. In this study, lupeol, a pentacyclic triterpene isolated from Crataeva nurvala stem bark, and its ester, lupeol linoleate, were investigated for their possible hypocholesterolaemic effects against cyclophosphamide-induced lipidaemic instabilities. Male albino Wistar rats were categorized into 6 groups. Group I served as control. Rats in groups II, V and VI were injected intraperitoneally with a single dose of cyclophosphamide (200 mg kg(-1)) dissolved in saline. Cyclophosphamide-treated groups V and VI respectively received lupeol and lupeol linoleate (50 mg kg(-1)), dissolved in olive oil, for 10 days by oral gavage. Groups III and IV served as drug controls and were administered lupeol and lupeol linoleate, respectively. Cyclophosphamide administration induced abnormal changes in serum lipoproteins and lipid fractions in both serum and cardiac tissue. The activity of lipid metabolizing enzymes was distorted significantly in the cyclophosphamide-treated rats. The cyclophosphamide-treated rats also showed extensive intermuscular haemorrhage in histology. Lupeol and its ester reversed the above alterations induced by cyclophosphamide. This study encapsulates the early lipaemic abnormalities in the heart tissue of cyclophosphamide-treated rats. Treatment with lupeol linoleate was more effective than lupeol in rendering protection to the cardiac tissue challenged by cyclophosphamide.
Sudharsan
P T
PT
Department of Medical Biochemistry, Dr. ALM. Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600113, India.
Mythili
Y
Y
Sudhahar
V
V
Varalakshmi
P
P
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D031483:Capparaceae / Q000737:chemistry; D009202:Cardiomyopathies / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D003520:Cyclophosphamide; D006321:Heart / Q000187:drug effects; D006949:Hyperlipidemias / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000032:analysis; D008071:Lipoprotein Lipase / Q000378:metabolism; D008074:Lipoproteins / Q000032:analysis; D008297:Male; D009206:Myocardium / Q000201:enzymology / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D053978:Pentacyclic Triterpenes; D024301:Plant Bark / Q000737:chemistry; D051381:Rats; D002787:Sterol Esterase / Q000378:metabolism; D014315:Triterpenes / Q000302:isolation & purification / Q000494:pharmacology*; D008041:Linoleic Acids; D000094042:Lupanes
D000924:Anticholesteremic Agents; D003520:Cyclophosphamide; D008055:Lipids; D008071:Lipoprotein Lipase; D008074:Lipoproteins; D053978:Pentacyclic Triterpenes; D002787:Sterol Esterase; D014315:Triterpenes; C403497:lupeol linoleate; D008041:Linoleic Acids; D000094042:Lupanes; C031695:acid cholesterol ester synthetase; C010480:lupeol